



ASX and Media Release

Viralytics Expands Patent Coverage in the US Notice of US Patent Allowance

4 February 2014, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) has expanded the company's patent portfolio after a notice of allowance of an additional patent by the US Patent and Trademark Office (USPTO).

The use of Viralytics' lead product CAVATAK™ is already protected with a portfolio of patents across major world markets, including in the US for a number of Group A Coxsackie viruses (including CAVATAK™). This core portfolio covers the use of selected Coxsackie A viruses.

The additional patent in the US broadens patent protection across all Coxsackie A viruses and furthermore, the much wider Group-C human enteroviruses that attach to intercellular adhesion molecule-1 (ICAM-1) in the process of targeting and destroying cancer cells.

A notice of allowance indicates the intention of the USPTO to grant a patent after an administrative process is completed.

Dr Malcolm McColl, Viralytics Chief Executive Officer said, "This US patent will significantly expand Viralytics' intellectual property portfolio in the US to cover the broad use of all Group-C human enteroviruses, including CAVATAK™, that target and destroy cancerous cells following binding to cell surface expressed ICAM-1. The United States is the world's largest pharmaceutical market and broadening patent protection in this market is very valuable for Viralytics."

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company has fully enrolled a phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Viralytics has received regulatory approval from the



UK Medicines and Healthcare products Regulatory Agency and will commence the STORM trial at three prominent UK sites in early 2014.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.